welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial for Familial Adenomatous Polyposis Patients
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that an Independent Data Monitoring Committee (IDMC), following a planned interim futility analysis, recommended continuation of the company’s pivotal Phase 3 trial, CPP FAP-310, evaluating CPP-1X/sulindac for adults with familial adenomatous polyposis (FAP).
FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. For most FAP patients, current medical practice recommends a lifetime of periodic monitoring as well as surgeries (FAP-related events). These FAP-related events include surgical removal of the colon, rectum, surgical pouch, duodenum, and/or high risk adenomas.
expertly curated content related to this topic
-
Celecoxib and Tauro-Ursodeoxycholic Acid Co-Treatment Inhibits Cell Growth in Familial Adenomatous Polyposis Derived...Chemoprevention would be a desirable str...
-
The Proper Diagnostic Pathway of Gardner’s Syndrome: Role of the Dentist in the Early Detection of the Associated ...Gardner’s syndrome is a genetic diseas...
-
Guidelines for the Clinical Management of Familial Adenomatous PolyposisFamilial adenomatous polyposis (FAP) is ...
-
Prophylactic Colectomy: Rationale, Indications, and ApproachDiscerning the genetics of hereditary co...
-
@FAPStudyDo you suffer from F.A.P.? There's a cli...
-
Ileoanal Pouch Dysfunction and the Use of a Medena Catheter Following Hospital DischargeWith the advent of new surgical techniqu...
-
APC-Associated Polyposis ConditionsCLINICAL CHARACTERISTICS : APC-associate...
English
Portuguese
Spanish